Kuros Biosciences to Supply SeaSpine with Bone Graft

Kuros Biosciences signed a private label agreement to supply bone graft material to SeaSpine, which will market the products as OsteoCurrent in the U.S. and select markets in Europe, South America and the Middle East following regulatory approvals. Initial sales in the U.S. are slated to begin in 1H19.

Kuros’ proprietary synthetic bone graft...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us